Ibogaine Patents 1997-2005

The use of ibogaine in treating substance use disorders in human subjects was first observed by Howard Lotsof in 1962, for which he was later awarded U.S. Patent 4,499,096 in 1985. In 1969, Claudio Naranjo was granted a French patent for the use of ibogaine in psychotherapy. Data demonstrating ibogaine’s efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper et al. (1999) [1] and Mash et al. (2000) [2].

US Patent or Application Number
Owner/ Inventor

Application 20050288375, Published 29 Dec 2005

Method and composition for treating neuro-degenerative disorders Myriad Genetics, Salt Lake City, UT US Claims ibogaine (and other compounds) used with an NSAID “for treating and preventing neurodegenerative disorders like Alzheimer’s disease, dementia, mild cognitive impairment.
Application 20050222270 published 6 Oct2005 and patent 5,958,919, issued 28 Sep 1999, and others Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis Washington University, St.Louis, MO US Use of ibogaine to enhance safety ina technique to “ease problems suchas addictions to illegal or pain-killing drugs, nicotine, or alcohol, compulsive or criminal behavioral problems, severe depression, obsessive-compulsive disorders,phobias, etc.
Patent 6,416,793, issued 9 Jul 2002 Formulations and use of controlled-release indolealkaloids BioResponse, LLC, Boulder,CO. US Ibogaine (and yohimbe) formulations with enhanced absorption by the body
Patent 6,348,456, issued 19 Feb 2002, and Application 20030153552, published 14 Aug 2003 Method of treating chemical dependency in mammals and a composition therefor Mash; Deborah C. (University of Miami professor)and co-inventors Claims noribogaine, a variant of ibogaine suitable for pharmaceuticals, and its use to treat addiction to “heroin, cocaine, alcohol, nicotine, amphetamine, methamphetamine, opium, methadone, hycodan, morphine and caffeine
Patent 6,211,360, issued 3 April 2001 Ibogamine cogeners Albany Medical College (Albany,NY, US) and the University of Vermont (US). Ibogamine-derived compounds for treating drug addiction
Patent 5,616,575, issued 1 Apr 1997 Bioactive tricyclicibogaine analogs University of Minnesota, US and University of Miami, US Ibogamine-derived compounds for treating drug addiction

[1] Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999).“Treatment of acute opioid withdrawal with ibogaine” (PDF). Am J Addict 8 (3): 234–42.

[2] Mash DC, Kovera CA, Pablo J, et al. (September 2000). “Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures”. Ann. N. Y. Acad. Sci. 914: 394–401.